Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases.
The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients.
It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis, cystic fibrosis, and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension.
The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 9, 24 | -1.06 Increased by +9.40% | -1.23 Increased by +13.82% |
| Feb 22, 24 | -1.28 Decreased by -5.79% | -1.15 Decreased by -11.30% |
| Oct 26, 23 | -1.11 Decreased by -1.83% | -1.13 Increased by +1.77% |
| Aug 3, 23 | -1.78 Decreased by -122.50% | -1.13 Decreased by -57.52% |
| May 4, 23 | -1.17 Decreased by -46.25% | -1.11 Decreased by -5.41% |
| Feb 23, 23 | -1.21 Decreased by -27.37% | -1.04 Decreased by -16.35% |
| Oct 27, 22 | -1.09 Decreased by -22.47% | -0.89 Decreased by -22.47% |
| Aug 4, 22 | -0.80 Increased by +12.09% | -0.89 Increased by +10.11% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 79.07 M Increased by +16.75% | -158.93 M Decreased by -21.19% | Decreased by -201.00% Decreased by -3.81% |
| Jun 30, 23 | 77.23 M Increased by +18.41% | -244.81 M Decreased by -155.96% | Decreased by -316.99% Decreased by -116.16% |
| Mar 31, 23 | 65.21 M Increased by +22.80% | -159.76 M Decreased by -68.85% | Decreased by -244.98% Decreased by -37.50% |
| Dec 31, 22 | 59.30 M Increased by +5.66% | -160.12 M Decreased by -41.73% | Decreased by -270.02% Decreased by -34.14% |
| Sep 30, 22 | 67.73 M Increased by +44.86% | -131.15 M Decreased by -16.35% | Decreased by -193.63% Increased by +19.68% |
| Jun 30, 22 | 65.22 M Increased by +43.77% | -95.64 M Increased by +18.48% | Decreased by -146.65% Increased by +43.29% |
| Mar 31, 22 | 53.11 M Increased by +32.06% | -94.62 M Decreased by -3.25% | Decreased by -178.17% Increased by +21.82% |
| Dec 31, 21 | 56.12 M Increased by +35.52% | -112.98 M Decreased by -10.53% | Decreased by -201.30% Increased by +18.44% |